Biohaven Ltd. Overview
Pro stress-test →Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. Following Pfizer's acquisition of the original Biohaven, the company spun off Biohaven Ltd., which retained the non-CGRP development stage pipeline including Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms.
Strategic Profile
Pro stress-test →Biohaven is a leader in targeted extracellular protein degradation with its MoDE and TRAP degraders, utilizing ground-breaking science exclusively licensed from Yale. The company announced a restructuring to target a ~60% reduction in annual direct R&D spend while accelerating pivotal trials for degraders and opakalim in 2026.
Competitive Landscape
Pro stress-test →Competitors include Neurogene, CuraSen, Quince Therapeutics, ACADIA Pharmaceuticals, and Biogen in the biopharmaceutical space. Biohaven differentiates through its proprietary MoDE and TRAP degrader platforms, with exclusive Yale licensing providing technological moat in extracellular protein degradation.
Industry Context
Biohaven Ltd. operates in Biopharmaceutical Development.
Key facts
Founded: 2022 · Headquarters: New Haven, Connecticut · Market cap: $1.58B